WASHINGTON — Scott Gottlieb, commissioner of the Food and Drug Administration, announced new steps the agency would take to promote the use and development of medication-assisted treatment for substance use disorder at a House hearing on Wednesday.

Gottlieb also rapped the insurance industry for what he called “often inadequate” coverage of existing therapies that combine counseling and medication-assisted treatment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • It is interesting that FDA plans to treat one abuse of medication with pushing the use of another medication – which may turn out to be as addictive or may have additional side effects. It almost seems as if Trump waited to declare emergency funds release till a pharma company to profit from opiod crisis could be identified?

    • Sagar, follow the medical evidence instead of your biases. MAT is the most effective treatment for opioid dependence.
      There are multiple companies involved in making these drugs. Methadone has been generic for decades, and the most used formulation of buprenorphine is also generic.
      “Pharma” is not singular or monolithic.

    • Addiction and dependence are two different things. Buprenorphine is fading and changing millions of addicts lives. Although I am still an “addict” according to you, in the past couple years I’ve gone from spending all my time and money on drugs to having an actual career, relationship, and just bought my first home. It’s given me my life back, and no, I don’t get any sort of”buzz” or “high” from it. Your comment is ignorant and dangerous, potentially discouraging people and parents from seeking effective help for themslves and loved ones rather than letting them die slowly in a revolving door of rehab/detox.

  • Amazing. Asking the pharmaceutical industry, that made billions off selling opioids, to now develop new drugs to treat the addictions they created. Not a solution. Not prevention. Just more profits. Clearly the FDA is in the pocket of pharma.

  • Why is the American medical establishment refusing to consider the use of Ibogaine in opioid addiction treatment? This drug is used throughout Europe, Canada and Mexico, but Americans must travel outside the country to use it, and American insurance refuses to cover it.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy